D-0665-2024 Class II Ongoing

Recalled by AbbVie Inc. — North Chicago, IL

FDA drug recall D-0665-2024 was initiated by AbbVie Inc. on Sep 16, 2024 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal. The recall status is ongoing. Affected quantity: 763,426 tubes.

Recall details

Product Type
Drugs
Report Date
Oct 2, 2024
Initiation Date
Sep 16, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
763,426 tubes

Product description

Refresh LACRI-LUBE, (42.5% Mineral Oil, 57.3% White Petrolatum) Lubricant Eye Ointment, Net wt, 0.12 oz (3.5g) Tube, Distributed by: Allergen, an AbbVie company, Madison, NJ 07940, UPC code: 300230312042

Reason for recall

Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

Distribution pattern

Nationwide in the USA, Foreign Consignees (Austrailia, Canada, Great Britain)

Code information

Lot: 387489, Exp. Oct 24; 387490, Exp. Jun 25; 390422, Exp. Nov 24; 390424, Exp. Oct 24; 391692, Exp. Jun 25; 391893, Exp. Nov 25; 394822, Exp. Feb 26; 395991, Exp. Mar 26; 397905, 397973, 397974, Exp May 26; 399019, 399254, Exp. Jun 26; 399922, Exp. Jul 26; 408738, Exp. Mar 27; T3911, Exp. Sep 24; T4015, T4031, T4032, T4033, T4108, Exp. Oct 24.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0665-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0665-2024. Report a data issue: hello@regdatalab.com.